|
| Index | - | P/E | 2.02 | EPS (ttm) | 3.40 | Insider Own | - | Shs Outstand | 32.32M | Perf Week | -4.85% |
| Market Cap | 222.33M | Forward P/E | 89.09 | EPS next Y | 0.08 | Insider Trans | - | Shs Float | 26.74M | Perf Month | -50.61% |
| Income | 113.70M | PEG | - | EPS next Q | -1.04 | Inst Own | 4.70% | Short Float | 0.03% | Perf Quarter | -69.87% |
| Sales | 186.60M | P/S | 1.19 | EPS this Y | 18.10% | Inst Trans | 14.59% | Short Ratio | 0.42 | Perf Half Y | -34.35% |
| Book/sh | 8.41 | P/B | 0.82 | EPS next Y | -98.47% | ROA | 51.00% | Target Price | 34.47 | Perf Year | - |
| Cash/sh | 9.40 | P/C | 0.73 | EPS next 5Y | - | ROE | 70.10% | 52W Range | 5.92 - 32.04 | Perf YTD | -64.23% |
| Dividend | - | P/FCF | 2.07 | EPS past 5Y | - | ROI | -55.90% | 52W High | -78.59% | Beta | - |
| Dividend % | - | Quick Ratio | 10.00 | Sales past 5Y | - | Gross Margin | - | 52W Low | 15.88% | ATR | 0.71 |
| Employees | 163 | Current Ratio | 10.00 | Sales Q/Q | 16.80% | Oper. Margin | 61.10% | RSI (14) | 25.00 | Volatility | 5.03% 5.73% |
| Optionable | No | Debt/Eq | 0.02 | EPS Q/Q | 443.90% | Profit Margin | 60.90% | Rel Volume | 3.80 | Prev Close | 6.88 |
| Shortable | Yes | LT Debt/Eq | 0.02 | Earnings | - | Payout | 0.00% | Avg Volume | 21.65K | Price | 6.86 |
| Recom | 2.00 | SMA20 | -2.92% | SMA50 | -53.86% | SMA200 | -63.67% | Volume | 82,146 | Change | -0.34% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite